Haemonetics Corporation (HAE)
| Market Cap | 5.39B +118.0% |
| Revenue (ttm) | 1.35B +0.4% |
| Net Income | 96.29M -41.1% |
| EPS | 2.06 -37.2% |
| Shares Out | 45.50M |
| PE Ratio | 57.56 |
| Forward PE | 21.51 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 777,377 |
| Open | 115.50 |
| Previous Close | 116.16 |
| Day's Range | 115.49 - 119.20 |
| 52-Week Range | 48.98 - 123.77 |
| Beta | 0.61 |
| Analysts | Buy |
| Price Target | 124.50 (+5.05%) |
| Earnings Date | Nov 5, 2026 |
About HAE
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management syst... [Read more]
Financial Performance
In fiscal year 2026, Haemonetics's revenue was $1.33 billion, a decrease of -1.97% compared to the previous year's $1.36 billion. Earnings were $97.31 million, a decrease of -41.97%.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for HAE stock is "Buy." The 12-month stock price target is $124.5, which is an increase of 5.05% from the latest price.
News
Haemonetics says FDA approves PerQseal Elite vascular closure system
Haemonetics (HAE) announced U.S. FDA approval of the PerQseal Elite vascular closure system for large-bore arterial procedures. The approval expands Haemonetics’ portfolio of clinically-differentiated...
Haemonetics Announces FDA Approval of PerQseal® Elite Vascular Closure System
BOSTON, Oct. 19, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today an...
Haemonetics price target raised to $140 from $95 at Mizuho
Mizuho analyst Anthony Petrone raised the firm’s price target on Haemonetics (HAE) to $140 from $95 and keeps an Outperform rating on the shares after the company updated its previously…
Haemonetics price target raised to $140 from $118 at Barrington
Barrington raised the firm’s price target on Haemonetics (HAE) to $140 from $118 and keeps an Outperform rating on the shares. The firm updated the company’s model to reflect its…
Haemonetics price target raised to $140 from $120 at BofA
BofA raised the firm’s price target on Haemonetics (HAE) to $140 from $120 and keeps a Buy rating on the shares after CSL announced that it will transition away from…
Why Is Haemonetics Stock (HAE) Up Over 13% Today?
Haemonetics stock gained after the company released a new SEC filing covering a supply agreement with CSL Plasma.
Haemonetics Stock Surges as Plasma Deal Opens Door to More Revenue
CSL Plasma plans to use Haemonetics' plasma collection equipment across all existing U.S. centers, expanding the scope of an earlier supply agreement.
Haemonetics price target raised to $130 from $110 at BTIG
BTIG raised the firm’s price target on Haemonetics (HAE) to $130 from $110 and keeps a Buy rating on the shares after CSL confirmed it anticipates transitioning to the company’s…
Morning Movers: Haemonetics up sharply after CSL Plasma supply pact
Stock futures are lower as a renewed jump in oil prices and Treasury yields revives inflation concerns. Brent crude jumped nearly 5% to above $105 a barrel, while WTI climbed…
Haemonetics enters non-exclusive supply agreement with CSL Plasma
In a regulatory filing, Haemonetics (HAE) disclosed its entry into a non-exclusive supply agreement with CSL Plasma, under which CSL may utilize the company’s NexSys PCS devices with Persona PLUS…
Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2027 Results: November 5, 2026
BOSTON, Sept. 30, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish second quarter fiscal year 2027 financial results at 6:00 am ET on Thursday, No...
Citi upgrades Haemonetics to Buy on CSL deal upside
Citi upgraded Haemonetics (HAE) to Buy from Neutral with a price target of $123, up from $92. The firm cites potential upside from the company’s non-exclusive supply agreement with CSL…
Haemonetics upgraded to Buy from Neutral at Citi
Citi upgraded Haemonetics (HAE) to Buy from Neutral with a $123 price target
Orchestra BioMed receives $6.1M milestone payment from Haemonetics
Orchestra BioMed (OBIO) announced the receipt of $6.1M as the first milestone payment in connection with the previously announced acquisition of Vivasure Medical by Haemonetics (HAE). This second paym...
Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics
Payment follows approximately $5 million received in January 2026, bringing total cash proceeds received to approximately $11 million Company remains eligible for up to approximately $10 million in ad...
Haemonetics price target raised to $125 from $105 at Raymond James
Raymond James analyst Andrew Cooper raised the firm’s price target on Haemonetics (HAE) to $125 from $105 and keeps an Outperform rating on the shares. The recent disclosure of CSL’s…
Haemonetics price target raised to $119 from $96 at Baird
Baird raised the firm’s price target on Haemonetics (HAE) to $119 from $96 and keeps an Outperform rating on the shares.
Haemonetics price target raised to $118 from $95 at Barrington
Barrington raised the firm’s price target on Haemonetics (HAE) to $118 from $95 and keeps an Outperform rating on the shares. The company disclosed a supply agreement under which CSL…
Haemonetics announces supply agreement with CSL Plasma
In a regulatory filing this morning, the company stated: “On August 14, 2026, Haemonetics (HAE) Corporation entered into a supply agreement with CSL Plasma Inc. pursuant to which CSL may…
Haemonetics Earnings Call Transcript: Q1 2027
Revenue grew 6% year-over-year to $339 million, with all core platforms contributing to profitable growth and adjusted EPS up 4%. FY27 revenue and earnings guidance were raised, supported by strong plasma and MedSurg performance, robust cash flow, and continued innovation momentum.
Haemonetics Slides: Q1 2027
Haemonetics has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on August 6, 2026.